Larkspur Biosciences

Larkspur Biosciences is a private, preclinical-stage biotech leveraging targeted protein degradation (TPD) to tackle adaptive resistance in cancer. The company's platform targets 'fitness genes'—proteins essential for tumor survival under stress—to unleash multiple anti-tumor mechanisms. Led by a seasoned team with deep experience in drug discovery and development from Novartis and GSK, and founded by renowned scientists like Lewis Cantley, Larkspur is advancing its lead candidate, LRK-4189, for difficult-to-treat cancers. The company is positioned in the high-potential but competitive TPD field, aiming to address significant unmet needs in oncology.

Targeted protein degradation (TPD) platform focused on designing heterobifunctional degraders (e.g., PROTACs) that eliminate specific 'cancer fitness genes'—proteins conditionally essential for tumor survival under stress.

Larkspur competes in the crowded targeted protein degradation field against public companies like Arvinas, Nurix Therapeutics, Kymera Therapeutics, and C4 Therapeutics, as well as internal programs at major pharma. Its differentiation hinges on its specific focus on conditionally essential 'fitness genes' rather than canonical oncogenic drivers.